A REVOLUTIONARY INNOVATION: Brain-on-a-chip technology to study neurodegenerative diseases

NOTE: THIS EVENT HAS BEEN POSTPONED DUE TO UNFORESEEN CIRCUMSTANCES UNTIL FURTHER NOTICE. REGISTRANTS, WE WILL KEEP YOU INFORMED ABOUT THE DATE, ONCE IT IS FINALIZED. Sorry for any inconveniences caused. 

 

A REVOLUTIONARY INNOVATION: Brain-on-a-chip technology to study neurodegenerative diseases

(Interested, but can’t attend? Register anyway and we’ll send you a link to the recording.)

Are you involved in drug development for neurodegenerative medicines?

This is your opportunity to evaluate and provide feedback on an exclusive, one-of-a-kind technology that has the potential to serve as a complement and, to a certain extent, as a substitute to currently used in vitro (2D) and in vivo (rodent) models for developing new neurodegenerative medicines.

The patented “Braingineering” technology is the first flexible, Brain-on-a-Chip platform for medium-to-high throughput screening (screening 13 compounds every 6 weeks). This technology mimics the environment of the brain in the CNS drug development process.

As a service to the industry, the technology will provide a tool to identify the most promising drug candidates for human clinical trials. This will result in significant savings for the industry in development time and costs. 

The Developmental and Cellular Biology at the Luxembourg Centre for Systems Biomedicine (LCSB) has established new human three-dimensional (3D) culture models for human nervous system tissue, so called brain organoids. These organoids are complex in their cellular composition and spatial organization, just as the human brain is. Furthermore, by utilizing microfluidics technology it was possible to establish these organoids on micro-devices, so called brain-on-a-chip. The whole method is based on induced pluripotent stem cells (iPSC). The team is creating a Contract Research Organization (CRO) with a focus on brain tissue engineering to provide organizations with drug screening services in drug discovery and pre-clinical testing. 

The feedback from potential users of this technology will help the team better understand the expectations that their technology must meet. 

With the ability to reproduce various elements of the brain, the “Braingineering” platform has the expertise to:  

– Increase efficiency: fuel the drug discovery phase with more compounds that could hold the potential to treat a specific neurodegenerative disease and

– Enhance relevance: sharpen and target more efficiently the compound candidates to go into the pre-clinical phase, which then increases the success rate further downstream.

This webinar provides you with a front-row seat to hear about this new technology and science. 

Join us for this webinar to evaluate this technology entitled “A REVOLUTIONARY INNOVATION: Brain-on-a-chip technology to study neurodegenerative diseases” on Thursday, July 7th at 11am EST. 

BRAIN-ON-A-CHIP PLATFORM

The global neurodegenerative diseases market is expected to grow from $8.8 billion in 2012 to $11 billion in 2018, comprised of Alzheimer’s disease and Parkinson’s disease, to name a few. 

The requirements for animal testing could be dramatically reduced.

By attending, you will have the opportunity to listen to a presentation on the technology, ask questions, and evaluate the technology (anonymously).

 

---

PANELISTS
	SPEAKER: Silvia Bolognin Post Doc (CTO in Spin-off) Braingineering Technologies (dedicated spin-off of Luxembourg Centre for Systems Biomedicine)
	SPEAKER: Dr. Stephanie Smith-Eckhardt Business Developer (CEO in Spin-off) Braingineering Technologies (dedicated spin-off of Luxembourg Centre for Systems Biomedicine)
	MODERATOR: Dawn Van Dam President & CEO One Million Solutions in Health™

SIGN ME UP FOR THIS SIGNATURE SQUARE EVENT: Click HERE